Clinical efficacy and safety of budesonide-formoterol in non-cystic fibrosis bronchiectasis

Chest

Volumn 141, Issue 2, 2012, Pages 461-468

  Martínez García, Miguel Ángel ^a,b,c   Soler Cataluña, Juan J ^a   Catalán Serra, Pablo ^a   Román Sánchez, Pilar ^a   PerpiñáTordera, Miguel ^b  

^a General Hospital of Requena   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; RILAST TURBUHALER; UNCLASSIFIED DRUG;

ADULT; ADVERSE DRUG REACTION; AGED; APHTHOUS ULCER; ARTICLE; BRONCHIECTASIS; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPHONIA; DYSPNEA; FEMALE; FUNCTIONAL ASSESSMENT; GINGIVITIS; HEALTH STATUS; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; LUNG FUNCTION; MALE; MICROORGANISM; NERVOUSNESS; PHARYNGEAL IRRITATION; PHARYNX DISEASE; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TACHYCARDIA; TASTE DISORDER; THORAX RADIOGRAPHY; THRUSH; TREMOR; UNSPECIFIED SIDE EFFECT; WHEEZING; XEROSTOMIA;

EID: 84856735509     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.11-0180     Document Type: Article

References (24)

1. O'Donnell AE. Bronchiectasis. Chest. 2008;134(4):815-823.
2. Martínez-García MA, PerpiñáM, Román P, Soler-Cataluña JJ. Quality-of-life determinants in patients with clinically stable bronchiectasis. Chest. 2005;128(2):739-745. (Pubitemid 41140504)
3. ten Hacken NH, Wijkstra PJ, Kerstjens HA. Treatment of bronchiectasis in adults. BMJ. 2007;335(7629):1089-1093. (Pubitemid 350206282)
4. Vendrell M, de Gracia J, Olveira C, et al. Diagnosis and treatement of bronchiectasis. Spanish Society of Pneumology and Thoracic Surgery [in Spanish]. Arch Bronconeumol. 2008;44(11):629-640.
5. Banov C, Howland WC III, Lumry WR, Parasuraman B, Uryniak T, Liljas B. Budesonide turbuhaler delivered once daily improves health-related quality of life in adult patients with non-steroid-dependent asthma. Allergy Asthma Proc. 2003;24(2):129-136. (Pubitemid 37034199)
6. Calverley PM, Anderson JA, Celli B, et al; TORCH investigators . Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775-789. (Pubitemid 46294610)
7. Jones PW. Clinical effects of inhaled corticosteroids in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2004;1(3):167-170.
8. Elborn JS, Johnston B, Allen F, Clarke J, McGarry J, Varghese G. Inhaled steroids in patients with bronchiectasis. Respir Med. 1992;86(2):121-124.
9. Tsang KW, Tan KC, Ho PL, et al. Inhaled fluticasone in bronchiectasis:a 12 month study. Thorax. 2005;60(3):239-243. (Pubitemid 40380285)
10. Martínez-García MA, Perpiñá-Tordera M, Román-Sánchez P, Soler-Cataluña JJ. Inhaled steroids improve quality of life in patients with steady-state bronchiectasis. Respir Med. 2006;100(9):1623-1632. (Pubitemid 44089352)
11. Tsang KW, Ho PL, Lam WK, et al. Inhaled fluticasone reduces sputum inflammatory indices in severe bronchiectasis. Am J Respir Crit Care Med. 1998;158(3):723-727. (Pubitemid 28449432)
12. Ducharme FM, Ni Chroinin M, Greenstone I, Lasserson TJ. Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database Syst Rev. 2010;5(5):CD005535.
13. Nannini LJ, Cates CJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus inhaled steroids for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2007;(4):CD006826 [Review].
14. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention NHLBI/WHO Workshop Report. Updated 2009. Global Initiative for Asthma Web site. http://www.ginasthma.com. Accessed April 2010.
15. Warwick WJ, Huang NN, Waring WW, et al. Evaluation of a cystic fibrosis screening system incorporating a miniature sweat stimulator and disposable chloride sensor. Clin Chem. 1986;32(5):850-853. (Pubitemid 17028364)
16. Naidich DP, McCauley DI, Khouri NF, Stitik FP, Siegelman SS. Computed tomography of bronchiectasis. J Comput Assist Tomogr. 1982;6(3):437-444. (Pubitemid 12123025)
17. Bhalla M, Turcios N, Aponte V, et al. Cystic fibrosis: scoring system with thin-section CT. Radiology. 1991;179(3):783-788.
18. Roca J, Sanchis J, Agusti-Vidal A, et al. Spirometric reference values from a Mediterranean population. Bull Eur Physiopathol Respir. 1986;22(3):217-224. (Pubitemid 16116729)
19. Martínez-García MA, PerpiñáTordera M, Román P, Soler- Cataluña JJ. Internal consistency and validity of the Spanish version of St. George's respiratory questionnaire for use in patients with clinically stable bronchiectasis in Spanish]. Arch Bronconeumol. 2005;41(3):110-117. (Pubitemid 40469296)
20. Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respir Med. 1991;85(suppl B):25-31.
21. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest. 1984;85(6):751-758. (Pubitemid 14121920)
22. Fuschillo S, De Felice A, Balzano G. Mucosal inflammation in idiopathic bronchiectasis:cellular and molecular mechanisms. Eur Respir J. 2008;31(2):396-406.
23. Mak JCW, Nishikawa M, Shirasaki H, Miyayasu K, Barnes PJ. Protective effects of a glucocorticoid on downregulation of pulmonary beta 2-adrenergic receptors in vivo. J Clin Invest. 1995;96(1):99-106.
24. Pang L, Knox AJ. Synergistic inhibition by beta(2)-agonists and corticosteroids on tumor necrosis factor-alpha-induced interleukin-8 release from cultured human airway smooth-muscle cells. Am J Respir Cell Mol Biol. 2000;23(1):79-85. (Pubitemid 30597098)